Atamparib for advanced lung cancer with KRAS mutation
Part of Brain & nervous system clinical trials.
This trial tests a drug called Atamparib for people with advanced lung cancer that has a specific genetic change called a KRAS mutation. It is for patients whose cancer has continued to grow after at least one standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a type of lung cancer called non-small cell lung adenocarcinoma that has spread and cannot be removed by surgery
- Your tumor must have a KRAS mutation
- You must have had at least one standard treatment and your cancer got worse after it
- Your tumors must be measurable on scans
- You must be able to take care of yourself (ECOG score 0 or 1)
- Your liver, kidneys, and bone marrow must work well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
This trial tests a combination of three drugs (trametinib, anlotinib, and tislelizumab) for people with KRAS-mutant non-small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This early-stage trial tests a new drug called LT-010391 designed to target a specific genetic mutation (KRAS G12D) found in some solid tumors. It's for patients whose cancer has progressed despite standard treatments or who cannot tolerate them.
This trial tests an oral targeted drug called Garsorasib for people with advanced lung cancer that has a specific KRAS G12C mutation and has not received previous treatment for advanced disease. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.
Hear when a new NSCLC Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.